Literature DB >> 3752956

Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate.

D H Ho, L Townsend, M A Luna, G P Bodey.   

Abstract

Dihydrouracil dehydrogenase activity, with 5-fluorouracil used as the substrate, was measured in human tissues and leukemic cells. The liver had the highest enzyme activity (mean, 705 nmoles/g tissue/hr) with minimal activity found in the kidneys, spleen, lung, colon, colon tumors, pancreas, breast tissue, breast tumors, bone marrow cells, and peripheral leukemic cells. Wide variations in the enzyme activities were noted in samples collected from different subjects. 5-diazouracil inhibits the enzyme activity with the concentration required for inhibiting 50% (IC50) of the liver enzyme being 3 microM. Other compounds, thymine, thymidine, 6-methoxydiazouracil, and cyclo-5-diazouridine were also tested for their effect on this enzyme. With the exception of cyclo-5-diazouridine, all others produced inhibitory effect. The inhibitory effect of 6-methoxydiazouracil is similar to that of diazouracil. Thymidine and thymine are less active with identical values for IC50 of 80 microM.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752956

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

1.  Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

Authors:  Suminobu Ito; Takeshi Kawamura; Makoto Inada; Yoshiharu Inoue; Yukihiro Hirao; Toshihisa Koga; Jun-ichi Kunizaki; Takefumi Shimizu; Hitoshi Sato
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 2.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer.

Authors:  Shigeki Nakayama; Shin Takeda; Yoshihisa Kawase; Soichiro Inoue; Tetsuya Kaneko; Akimasa Nakao
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

5.  Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil.

Authors:  D Dobritzsch; G Schneider; K D Schnackerz; Y Lindqvist
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

Review 6.  Clinical pharmacokinetics of capecitabine.

Authors:  B Reigner; K Blesch; E Weidekamm
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.

Authors:  G W Visser; G C Gorree; G J Peters; J D Herscheid
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase.

Authors:  Ritsuto Fujiwaki; Kohji Iida; Kentaro Nakayama; Haruhiko Kanasaki; Tomoya Ozaki; Kohkichi Hata; Eiichi Sakai; Kohji Miyazaki
Journal:  Virchows Arch       Date:  2003-08-09       Impact factor: 4.064

9.  Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.

Authors:  Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

10.  Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system.

Authors:  E C Spoelstra; H M Pinedo; H Dekker; G J Peters; J Lankelma
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.